Recent Research Analysts’ Ratings Updates for Palisade Bio (PALI)

Palisade Bio (NASDAQ: PALI) has recently received a number of price target changes and ratings updates:

• 6/30/2026 – Palisade Bio was given a new $7.00 price target by Oppenheimer Holdings, Inc..
• 6/30/2026 – Palisade Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock.
• 6/29/2026 – Palisade Bio was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/27/2026 – Palisade Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/25/2026 – Palisade Bio was upgraded by LADENBURG THALM/SH SH to “strong-buy”.
• 6/9/2026 – Palisade Bio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.